CSPC Pharma weighs up diet drug for bigger bottom line
After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business Key Takeaways: CSPC…
Recent Articles
RECENT ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
